3151 Stock Overview
Vital KSK Holdings, Inc. engages in the wholesale and retail sale of pharmaceutical products in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Vital KSK Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,202.00 |
| 52 Week High | JP¥1,378.00 |
| 52 Week Low | JP¥878.00 |
| Beta | 0.070 |
| 1 Month Change | -5.95% |
| 3 Month Change | 5.35% |
| 1 Year Change | 25.60% |
| 3 Year Change | 70.98% |
| 5 Year Change | 13.40% |
| Change since IPO | 115.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3151 | JP Healthcare | JP Market | |
|---|---|---|---|
| 7D | 0.3% | 1.2% | 1.8% |
| 1Y | 25.6% | 4.1% | 31.0% |
Return vs Industry: 3151 exceeded the JP Healthcare industry which returned 4.1% over the past year.
Return vs Market: 3151 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 3151 volatility | |
|---|---|
| 3151 Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 3151 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3151's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 3,719 | Taisuke Murai | www.vitalksk.co.jp |
Vital KSK Holdings, Inc. engages in the wholesale and retail sale of pharmaceutical products in Japan. The company is involved in the nursing care, agrochemical wholesale, and veterinary drug wholesale business. It also engages in the medical and pharmacy consulting business.
Vital KSK Holdings, Inc. Fundamentals Summary
| 3151 fundamental statistics | |
|---|---|
| Market cap | JP¥60.34b |
| Earnings (TTM) | JP¥7.45b |
| Revenue (TTM) | JP¥585.49b |
8.1x
P/E Ratio0.1x
P/S RatioIs 3151 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3151 income statement (TTM) | |
|---|---|
| Revenue | JP¥585.49b |
| Cost of Revenue | JP¥538.00b |
| Gross Profit | JP¥47.49b |
| Other Expenses | JP¥40.04b |
| Earnings | JP¥7.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | 148.46 |
| Gross Margin | 8.11% |
| Net Profit Margin | 1.27% |
| Debt/Equity Ratio | 7.8% |
How did 3151 perform over the long term?
See historical performance and comparison